PDF) Lipopolysaccharide Animal Models for Parkinson's Disease
Frontiers | Altered Gut Microbiome in Parkinson's Disease and the Influence of Lipopolysaccharide in a Human α-Synuclein Over-Expressing Mouse Model
The Effects of Novel Formulations of Edaravone and Curcumin in the Mouse Intrastriatal Lipopolysaccharide Model of Parkinson's Disease
PDF) Inflammatory Animal Model for Parkinson's Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of Nigrostriatal Dopaminergic Neurons
Lipopolysaccharide animal models of Parkinson's disease: Recent progress and relevance to clinical disease - ScienceDirect
Parkinson's disease: a systemic inflammatory disease accompanied by bacterial inflammagens | bioRxiv
![PDF] Lipopolysaccharide Animal Models for Parkinson's Disease | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a63c762e0fa3c8d5b24bb90bbf75a3ae3fff0174/6-Figure1-1.png "PDF] Lipopolysaccharide Animal Models for Parkinson's Disease | Semantic Scholar")
PDF] Lipopolysaccharide Animal Models for Parkinson's Disease | Semantic Scholar
Parkinson's disease: Are gut microbes involved? | American Journal of Physiology-Gastrointestinal and Liver Physiology
Lipopolysaccharide animal models of Parkinson's disease: Recent progress and relevance to clinical disease - ScienceDirect
The Endotoxin-Induced Neuroinflammation Model of Parkinson's Disease
PDF) Effects of Adenosine Receptor Antagonists on the In Vivo LPS-Induced Inflammation Model of Parkinson's Disease | Jadwiga Wardas - Academia.edu
Neuroprotective Effect of Swertiamarin in a Rotenone Model of Parkinson's Disease: Role of Neuroinflammation and Alpha-Synuclein Accumulation | ACS Pharmacology & Translational Science
Lipopolysaccharide Animal Models for Parkinson's Disease
MicroRNA‐3473b regulates the expression of TREM2/ULK1 and inhibits autophagy in inflammatory pathogenesis of Parkinson disease - Lv - 2021 - Journal of Neurochemistry - Wiley Online Library
Intranasal LPS-Mediated Parkinson's Model Challenges the Pathogenesis of Nasal Cavity and Environmental Toxins | PLOS ONE
Pramipexole inhibits astrocytic NLRP3 inflammasome activation via Drd3-dependent autophagy in a mouse model of Parkinson's disease | Acta Pharmacologica Sinica
Frontiers | Genetic Imaging of Neuroinflammation in Parkinson's Disease: Recent Advancements
Lipopolysaccharide animal models of Parkinson's disease: Recent progress and relevance to clinical disease | Semantic Scholar
Characterization of the lipopolysaccharide induced model of Parkinson's disease: Role of oxidative stress and neuroinflammation - ScienceDirect
The influence of preconditioning with low dose of LPS on paraquat-induced neurotoxicity, microglia activation and expression of α-synuclein and synphilin-1 in the dopaminergic system | SpringerLink
Protective effects of DL‑3‑n‑butylphthalide in the lipopolysaccharide‑induced mouse model of Parkinson's disease
PDF) Further characterisation of the LPS model of Parkinson's disease: A comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat. | Pádraig Mulcahy -
Rg1 improves LPS-induced Parkinsonian symptoms in mice via inhibition of NF-κB signaling and modulation of M1/M2 polarization | Acta Pharmacologica Sinica
Urate inhibits microglia activation to protect neurons in an LPS-induced model of Parkinson's disease | Journal of Neuroinflammation | Full Text
IJMS | Free Full-Text | Licochalcone A Prevents the Loss of Dopaminergic Neurons by Inhibiting Microglial Activation in Lipopolysaccharide (LPS)-Induced Parkinson's Disease Models
IJMS | Free Full-Text | Tubeimoside I Protects Dopaminergic Neurons Against Inflammation-Mediated Damage in Lipopolysaccharide (LPS)-Evoked Model of Parkinson's Disease in Rats
